A paradigm shift in therapeutic vaccination of cancer patients: The need to apply therapeutic vaccination strategies in the preventive setting

Immunological Reviews

Volumn 222, Issue 1, 2008, Pages 316-327

  Gray, Andrew ^a   Raff, Adam B ^a   Chiriva Internati, Maurizio ^b,c   Chen, Si Yi ^a,d   Kast, W Martin ^a,d,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Cancer prevention; Immunotherapies; Therapeutic cancer vaccines; Tumor immunity; Vaccination

Indexed keywords

ANTIINFECTIVE AGENT; BASILIXIMAB; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELANOMA VACCINE; MELPHALAN; TUMOR ANTIGEN;

BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; CLINICAL TRIAL; CRYOTHERAPY; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG INHIBITION; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MELANOMA; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; REVIEW; UTERINE CERVIX CANCER;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VIRAL VACCINES;

EID: 41149097729     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00605.x     Document Type: Review

References (90)

1. Tjoa BA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and psma peptides. Prostate 1998 36 : 39 44.
2. Murphy GP, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999 39 : 54 59.
3. Eder JP, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000 6 : 1632 1638.
4. Small EJ, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000 18 : 3894 3903.
5. Fong L, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001 167 : 7150 7156.
6. Heiser A, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002 109 : 409 417.
7. Burch PA, et al. Immunotherapy (APC8015, provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004 60 : 197 204.
8. Kaufman HL, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the eastern cooperative oncology group. J Clin Oncol 2004 22 : 2122 2132.
9. Su Z, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005 174 : 3798 3807.
10. Fuessel S, et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006 66 : 811 821.
11. DiPaola RS, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006 4 : 1.
12. Small EJ, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-t (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006 24 : 3089 3094.
13. Thomas-Kaskel AK, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006 119 : 2428 2434.
14. Waeckerle-Men Y, et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006 55 : 1524 1533.
15. Noguchi M, et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007 67 : 933 942.
16. Uemura H, et al. A phase I trial of vaccination of CA9-derived peptides for hla-a24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006 12 : 1768 1775.
17. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 2006 50 : 34 43.
18. Berd D, Sato T, Cohn H, Maguire HC, Jr., Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 2001 94 : 531 539.
19. Markovic SN, et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 2006 29 : 352 360.
20. Gjertsen MK, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001 92 : 441 450.
21. Vonderheide RH, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004 10 : 828 839.
22. Gajewski TF, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006 213 : 131 145.
23. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005 5 : 263 274.
24. Klebanoff CA, Gattinoni L, Restifo NP. CD8+T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006 211 : 214 224.
25. Zimmermann VS, et al. Tumors hamper the immunogenic competence of CD4+ T cell-directed dendritic cell vaccination. J Immunol 2007 179 : 2899 2909.
26. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007 117 : 1167 1174.
27. Ercolini AM, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005 201 : 1591 1602.
28. Viehl CT, et al. Depletion of CD4+CD25+regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 2006 13 : 1252 1258.
29. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007 110 : 3192 3201.
30. Dannull J, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005 115 : 3623 3633.
31. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 2004 22 : 1546 1553.
32. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 2006 116 : 90 100.
33. Finn OJ. Premalignant lesions as targets for cancer vaccines. J Exp Med 2003 198 : 1623 1626.
34. Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev 2006 25 : 233 242.
35. Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 2007 110 : 203 214.
36. Lambeck AJ, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007 13 : 2385 2391.
37. Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007 56 : 81 87.
38. Mitchell MS. Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 2003 52 : 686 692.
39. Casati A, Zimmermann VS, Benigni F, Bertilaccio MT, Bellone M, Mondino A. The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration. J Immunol 2005 174 : 3317 3325.
40. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005 65 : 8059 8064.
41. Gulley JL, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005 11 : 3353 3362.
42. Small LA, et al. A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy. Clin Cancer Res 2001 7 : 876s 881s.
43. Hsueh EC, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002 20 : 4549 4554.
44. Berd D, Sato T, Maguire HC, Jr., Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004 22 : 403 415.
45. Hsueh EC, Famatiga E, Shu S, Ye X, Morton DL. Peripheral blood CD4+T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol 2004 11 : 892 899.
46. Takeuchi H, Morton DL, Elashoff D, Hoon DS. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005 117 : 1032 1038.
47. Chung MH, et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 2003 21 : 313 319.
48. Wallack MK, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997 226 : 198 206.
49. Weber J, et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 2003 97 : 186 200.
50. Sosman JA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002 20 : 2067 2075.
51. Livingston PO, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994 12 : 1036 1044.
52. Wang F, et al. Phase I trial of a MART-1 peptide vaccine with incomplete freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999 5 : 2756 2765.
53. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 2006 106 : 1353 1357.
54. Sanderson K, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005 23 : 741 750.
55. Kirkwood JM, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001 19 : 2370 2380.
56. Hsu FJ, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 1997 89 : 3129 3135.
57. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G FC receptor genotype. J Clin Oncol 2004 22 : 4717 4724.
58. Reinartz S, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004 10 : 1580 1587.
59. Berek JS, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004 22 : 3507 3516.
60. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997 80 : 42 49.
61. Giaccone G, et al. Phase III study of adjuvant vaccination with Bec2/bacille calmette-guerin in responding patients with limited-disease small-cell lung cancer (European organisation for research and treatment of cancer 08971-08971B; silva study). J Clin Oncol 2005 23 : 6854 6864.
62. Jaffee EM, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001 19 : 145 156.
63. Sportes C, et al. Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients. Biol Blood Marrow Transplant 2005 11 : 472 483.
64. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004 64 : 2205 2211.
65. Finn OJ, Forni G. Prophylactic cancer vaccines. Curr Opin Immunol 2002 14 : 172 177.
66. Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007 67 : 1344 1351.
67. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008 68 : 861 869.
68. Wang X, Wang JP, Maughan MF, Lachman LB. Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res 2005 7 : R145 R155.
69. Mwau M, et al. A human immunodeficiency virus 1 (HIV-1) clade a vaccine in clinical trials: stimulation of hiv-specific T-cell responses by DNA and recombinant modified vaccinia virus ankara (MVA) vaccines in humans. J Gen Virol 2004 85 : 911 919.
70. Hubert RS, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 1999 96 : 14523 14528.
71. Gu Z, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000 19 : 1288 1296.
72. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 2001 61 : 5857 5860.
73. Hale JS, Boursalian TE, Turk GL, Fink PJ. Thymic output in aged mice. Proc Natl Acad Sci USA 2006 103 : 8447 8452.
74. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007 67 : 1326 1334.
75. Muderspach L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000 6 : 3406 3416.
76. Roman LD, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007 106 : 558 566.
77. Einstein MH, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007 106 : 453 460.
78. Corona Gutierrez CM, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004 15 : 421 431.
79. Garcia-Hernandez E, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006 13 : 592 597.
80. Brinkman JA, et al. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007 23 : 337 352.
81. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007 7 : 79 89.
82. *0201-restricted E7-encoded epitope. Cancer Res 1996 56 : 582 588.
83. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007 13 : 3776 3782.
84. Antonia SJ, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006 12 : 878 887.
85. Arlen PM, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005 174 : 539 546.
86. Arlen PM, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006 12 : 1260 1269.
87. Salgaller ML, et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (psma). Prostate 1998 35 : 144 151.
88. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007 6 : 25.
89. Micke P, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease? Lung Cancer 2002 37 : 271 276.
90. Peoples GE, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005 23 : 7536 7545.